Abstract:The deacetylase sirtuin 1 (Sirt1), activated by calorie restriction and fasting, exerts several complementary effects on cellular function that are favourable to healthspan; it is often thought of as an 'anti-aging' enzyme. Practical measures which might boost Sirt1 activity are therefore of considerable interest. A number of nutraceuticals have potential in this regard. Nutraceuticals reported to enhance Sirt1 synthesis or protein expression include ferulic acid, tetrahydrocurcumin, urolithin A, melatonin, astaxanthin, carnosic acid and neochlorogenic acid. The half-life of Sirt1 protein can be enhanced with the natural nicotinamide catabolite N1-methylnicotinamide. The availability of Sirt1's obligate substrate NAD+ can be increased in several ways: nicotinamide riboside and nicotinamide mononucleotide can function as substrates for NAD+ synthesis; activators of AMP-activated kinase-such as berberine-can increase expression of nicotinamide phosphoribosyltransferase, which is rate limiting for NAD+ synthesis; and nutraceutical quinones such as thymoquinone and pyrroloquinoline quinone can boost NAD+ by promoting oxidation of NADH. Induced ketosis-as via ingestion of medium-chain triglycerides-can increase NAD+ in the brain by lessening the reduction of NAD+ mediated by glycolysis. Post-translational modifications of Sirt1 by O-GlcNAcylation or sulfonation can increase its activity, suggesting that administration of glucosamine or of agents promoting hydrogen sulfide synthesis may aid Sirt1 activity. Although resveratrol has poor pharmacokinetics, it can bind to Sirt1 and activate it allosterically-as can so-called sirtuin-activating compound drugs. Since oxidative stress can reduce Sirt1 activity in multiple ways, effective antioxidant supplementation that blunts such stress may also help preserve Sirt1 activity in some circumstances. Combination nutraceutical regimens providing physiologically meaningful doses of several of these agents, capable of activating Sirt1 in complementary ways, may have considerable potential for health promotion. Such measures may also amplify the benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors in non-diabetic disorders, as these benefits appear to reflect upregulation of Sirt1 and AMP-activated protein kinase activities.

Evidence for a Common Mechanism of SIRT1 Regulation by Allosteric Activators

A Novel Mechanism for SIRT1 Activators That Does Not Rely on the Chemical Moiety Immediately C-Terminal to the Acetyl-Lysine of the Substrate

Mechanism of allosteric activation of SIRT6 revealed by the action of rationally designed activators

Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol

Abstract 10153: SIRT1 Activation Restores Cardioprotection in the Aged Heart Against Ischemia/Reperfusion Injury

Deciphering the Allosteric Activation Mechanism of SIRT6 Using Molecular Dynamics Simulations

SIRT1 in metabolic syndrome: where to target matters.

Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo

The NAD+-dependent Protein Deacetylase Activity of SIRT1 is Regulated by Its Oligomeric Status

Nicotinamide Riboside Activates SIRT5 Deacetylation

Cross-talk between Sirtuin and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in the Regulation of S6 Kinase 1 (S6K1) Phosphorylation

Abstract 186: Impaired Nucleocytoplasmic Shuttling and Activity of SIRT1 in Response to Ischemic Stress in the Senescent Heart

Nutraceutical activation of Sirt1: a review

SIRT1 Activation by Natural Phytochemicals: An Overview

Resveratrol Serves As a Protein-Substrate Interaction Stabilizer in Human SIRT1 Activation

Activation and inhibition of sirtuins: From bench to bedside

Discovery and characterization of a new class of NAD+-independent SIRT1 activators

A fluorometric assay of SIRT1 deacetylation activity through quantification of nicotinamide adenine dinucleotide.

O-GlcNAcylation of SIRT1 Enhances Its Deacetylase Activity and Promotes Cytoprotection under Stress

Small Molecules as SIRT Modulators

Inhibitory protein–protein interactions of the SIRT1 deacetylase are choreographed by post‐translational modification